dc.contributor.author | Geva, R | |
dc.contributor.author | Lopez, J | |
dc.contributor.author | Danson, S | |
dc.contributor.author | Joensuu, H | |
dc.contributor.author | Peer, A | |
dc.contributor.author | Harris, SJ | |
dc.contributor.author | Souza, F | |
dc.contributor.author | Pereira, KMC | |
dc.contributor.author | Perets, R | |
dc.date.accessioned | 2020-04-28T10:39:44Z | |
dc.date.issued | 2019-05 | |
dc.identifier.citation | European journal of nuclear medicine and molecular imaging, 2019, 46 (5), pp. 1092 - 1101 | |
dc.identifier.issn | 1619-7070 | |
dc.identifier.uri | https://repository.icr.ac.uk/handle/internal/3602 | |
dc.identifier.eissn | 1619-7089 | |
dc.identifier.doi | 10.1007/s00259-018-4234-6 | |
dc.description.abstract | PURPOSE:Concomitant treatment with radium-223 and paclitaxel is a potential option for cancer patients with bone metastases; however, myelosuppression risk during coadministration is unknown. This phase Ib study in cancer patients with bone metastases evaluated the safety of radium-223 and paclitaxel. METHODS:Eligible patients had solid tumor malignancies with ≥2 bone metastases and were candidates for paclitaxel. Treatment included seven paclitaxel cycles (90 mg/m2 per week intravenously per local standard of care; 3 weeks on/1 week off) plus six radium-223 cycles (55 kBq/kg intravenously; one injection every 4 weeks, starting at paclitaxel cycle 2). The primary end point was percentage of patients with grade 3/4 neutropenia or thrombocytopenia during coadministration of radium-223 and paclitaxel (cycles 2, 3) versus paclitaxel alone (cycle 1). RESULTS:Of 22 enrolled patients, 15 were treated (safety population), with 7 completing all six radium-223 cycles. Treated patients had primary cancers of breast (n = 7), prostate (n = 4), bladder (n = 1), non-small cell lung (n = 1), myxofibrosarcoma (n = 1), and neuroendocrine (n = 1). No patients discontinued treatment from toxicity of the combination. In the 13 patients who completed cycle 3, the rates of grade 3 neutropenia in cycles 2 and 3 were 31% and 8%, respectively, versus 23% in cycle 1; there were no cases of grade 4 neutropenia or grade 3/4 thrombocytopenia. Breast cancer subgroup safety results were similar to the overall safety population. CONCLUSION:Radium-223 was tolerated when combined with weekly paclitaxel, with no clinically relevant additive toxicities. This combination should be explored further in patients with bone metastases. | |
dc.format | Print-Electronic | |
dc.format.extent | 1092 - 1101 | |
dc.language | eng | |
dc.language.iso | eng | |
dc.rights.uri | https://creativecommons.org/licenses/by/4.0 | |
dc.subject | Humans | |
dc.subject | Bone Neoplasms | |
dc.subject | Radium | |
dc.subject | Paclitaxel | |
dc.subject | Combined Modality Therapy | |
dc.subject | Safety | |
dc.subject | Aged | |
dc.subject | Middle Aged | |
dc.subject | Female | |
dc.subject | Male | |
dc.title | Radium-223 in combination with paclitaxel in cancer patients with bone metastases: safety results from an open-label, multicenter phase Ib study. | |
dc.type | Journal Article | |
dcterms.dateAccepted | 2018-12-03 | |
rioxxterms.versionofrecord | 10.1007/s00259-018-4234-6 | |
rioxxterms.licenseref.uri | https://creativecommons.org/licenses/by/4.0 | |
rioxxterms.licenseref.startdate | 2019-05 | |
rioxxterms.type | Journal Article/Review | |
dc.relation.isPartOf | European journal of nuclear medicine and molecular imaging | |
pubs.issue | 5 | |
pubs.notes | Not known | |
pubs.organisational-group | /ICR | |
pubs.organisational-group | /ICR/Primary Group | |
pubs.organisational-group | /ICR/Primary Group/ICR Divisions | |
pubs.organisational-group | /ICR/Primary Group/ICR Divisions/Cancer Therapeutics | |
pubs.organisational-group | /ICR/Primary Group/ICR Divisions/Cancer Therapeutics/Medicine (de Bono Prostate) | |
pubs.organisational-group | /ICR | |
pubs.organisational-group | /ICR/Primary Group | |
pubs.organisational-group | /ICR/Primary Group/ICR Divisions | |
pubs.organisational-group | /ICR/Primary Group/ICR Divisions/Cancer Therapeutics | |
pubs.organisational-group | /ICR/Primary Group/ICR Divisions/Cancer Therapeutics/Medicine (de Bono Prostate) | |
pubs.publication-status | Published | |
pubs.volume | 46 | |
pubs.embargo.terms | Not known | |
icr.researchteam | Medicine (de Bono Prostate) | |
dc.contributor.icrauthor | Lopez, Juanita | |